Loukas F Kontovinis

Summary

Publications

  1. ncbi Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
    Loukas Kontovinis
    Medical Oncology Unit, Theagenion Cancer Hospital, Al Simeonidi street 2, 54007, Thessaloniki, Greece
    Med Oncol 29:750-4. 2012
  2. ncbi Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma
    Konstantinos T Papazisis
    3rd Department of Medical Oncology, Theagenion Cancer Hospital, AL, Simeonidi str 2, 54007 Thessaloniki, Greece
    BMC Cancer 10:489. 2010
  3. ncbi Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
    Loukas F Kontovinis
    3rd Department of Medical Oncology, Theagenion Cancer Hospital, Al Simeonidi str 2, 54007, Thessaloniki, Greece
    BMC Cancer 9:82. 2009

Detail Information

Publications3

  1. ncbi Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
    Loukas Kontovinis
    Medical Oncology Unit, Theagenion Cancer Hospital, Al Simeonidi street 2, 54007, Thessaloniki, Greece
    Med Oncol 29:750-4. 2012
    ..The TTP with sorafenib following sunitinib was comparable to outcomes reported previously, providing further support that TKIs should be used in sequence before switching to an mTOR inhibitor...
  2. ncbi Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma
    Konstantinos T Papazisis
    3rd Department of Medical Oncology, Theagenion Cancer Hospital, AL, Simeonidi str 2, 54007 Thessaloniki, Greece
    BMC Cancer 10:489. 2010
    ..Although the majority of sunitinib-treated patients receive a clinical benefit, almost a third of the patients will not respond. Currently there is no available marker that can predict for response in these patients...
  3. ncbi Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
    Loukas F Kontovinis
    3rd Department of Medical Oncology, Theagenion Cancer Hospital, Al Simeonidi str 2, 54007, Thessaloniki, Greece
    BMC Cancer 9:82. 2009
    ..We assessed the outcome and plasma proangiogenic factors in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib in our institution...